Home / About Novasep / Media & Events / Press releases

Press releases

Novasep invests €10M to reinforce its bioconjugation services

25 Jun 2015

Expansion marks Novasep’s readiness for full range Antibody Drug Conjugates CMO services


Novasep launches BioSCĀ® Lab, next-generation biochromatography equipment for protein purification in batch and continuous modes

Novasep launches BioSC® Lab, next-generation biochromatography equipment for protein purification in batch and continuous modes

15 Jun 2015

Simulation software BioSC® PredictTM enables instant switch from batch to continuous modes

Winner of Achema 2015 Innovation Award


Novasep signs two deals to further develop its presence in Japan

08 Jun 2015

Allied Laboratories and AR Brown selected as local agents


Novasep appoints two executives to further strengthen its management team

05 May 2015

Pierre-Louis Mikus joins as chief legal officer; Bertrand Waymel is promoted to group human resources director


Novasep reports strong 2014 full year results

21 Apr 2015

- Swift execution of ‘Back to Basics’ strategic plan leading to successful portfolio reshaping
- All business units contributing to the strong performance
- 20% EBITDA growth driven by focus on attractive projects and cost control policy


Novasep and Celladon Execute MYDICAR API supply agreement

24 Mar 2015

Pompey, France, and San Diego, CA, USA, March 24, 2015 - Novasep, a leading supplier of services and technologies for the life sciences and chemical industries and Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.


Novasep selected to commercially biomanufacture Celladon’s Mydicar API

17 Feb 2015

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that it has entered into an agreement with Celladon, a clinical-stage biotechnology company. Novasep will prepare to supply the drug substance for MYDICAR®.


Novasep opens new office in Thailand

15 Dec 2014

Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.


Novasep and partner Nilsan Nishotech to install the first continuous chromatography system at Laurus Labs

13 Nov 2014

Novasep Varicol high-performance continuous chromatography technology brings productivity gains in an Indian-based API commercial production.



You can continue visiting and select more documents or directly download the one you selected.